Autologous Mesenchymal Stroma Cells Are Superior to Allogeneic Ones in Bone Defect Regeneration

International Journal of Molecular Sciences
Anna E RappAnita Ignatius

Abstract

The application of autologous mesenchymal stem cells (MSC) for the treatment of bone defects requires two invasive procedures and several weeks of ex vivo cell expansion. To overcome these limitations, the administration of allogeneic MSC may be attractive, because they are anticipated to be immunoprivileged. Because preclinical studies using various animal models are conflicting with respect to the efficacy of allogeneic MSC, we investigated whether autologous and allogeneic human MSC (hMSC) are equally effective in regenerating bone in a humanized mouse model resembling the human immune system. Applying autologous and allogeneic hMSC in critically sized femoral defects, we found that allogeneic hMSC elicited a mild immune response early after implantation, whereas early angiogenic processes were similar in both treatments. At later healing time points, the transplantation of allogeneic hMSC resulted in less bone formation than autologous hMSC, associated with a reduced expression of the osteogenic factor Runx2 and impaired angiogenesis. We found by species-specific staining for collagen-type-1α2 that MSCs of either source did not synthesize new bone matrix, indicating an indirect contribution of transplanted hMSC to bone rege...Continue Reading

References

Jan 1, 1989·Journal of Orthopaedic Trauma·J F ConnollyR Dehne
Jun 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Edwin M HorwitzTed Hofmann
Jul 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·John StreetEllen H Filvaroff
Oct 18, 2003·The Journal of Bone and Joint Surgery. American Volume·Treena Livingston ArinzehSudha Kadiyala
May 10, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leonard D ShultzRupert Handgretinger
Mar 4, 2006·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Chao WanGang Li
Jul 8, 2010·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·L de GirolamoA T Brini
Sep 28, 2010·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Viktoria RöntgenAnita Ignatius
Nov 26, 2010·Stem Cell Research & Therapy·Bruce A BunnellDeborah E Sullivan
Aug 14, 2012·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Abhijit S DigheQuanjun Cui
Mar 22, 2013·Science Translational Medicine·Simon ReinkeGeorg N Duda
Nov 19, 2013·Journal of Cellular and Molecular Medicine·Anindita ChatterjeaJan de Boer
Jan 6, 2016·The Journal of Clinical Investigation·Kai Hu, Bjorn R Olsen
Jun 10, 2017·Frontiers in Immunology·Thaqif El KhassawnaGeorg N Duda

❮ Previous
Next ❯

Citations

Apr 18, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Weiping LinGang Li
Jul 7, 2020·Xenotransplantation·Boon Ching Tee, Zongyang Sun
Oct 22, 2020·Journal of Translational Medicine·S ElgazP Bader
Oct 14, 2020·The Journal of Gene Medicine·Kai-De LiLei Liu
Oct 23, 2021·Frontiers in Cell and Developmental Biology·Marta S CarvalhoCláudia L da Silva

❮ Previous
Next ❯

Software Mentioned

MetaMorph
Plex [UNK]
CTAnalyser
Bio
GraphPad Prism
Leica MetaMorph
Excel

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.